IL162408A0 - Use of pramipexole to treat amyotrophic lateral scelrosis - Google Patents

Use of pramipexole to treat amyotrophic lateral scelrosis

Info

Publication number
IL162408A0
IL162408A0 IL16240802A IL16240802A IL162408A0 IL 162408 A0 IL162408 A0 IL 162408A0 IL 16240802 A IL16240802 A IL 16240802A IL 16240802 A IL16240802 A IL 16240802A IL 162408 A0 IL162408 A0 IL 162408A0
Authority
IL
Israel
Prior art keywords
pramipexole
amyotrophic lateral
scelrosis
treat amyotrophic
als
Prior art date
Application number
IL16240802A
Other languages
English (en)
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of IL162408A0 publication Critical patent/IL162408A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Artificial Filaments (AREA)
  • Noodles (AREA)
  • Medicinal Preparation (AREA)
IL16240802A 2001-12-11 2002-12-02 Use of pramipexole to treat amyotrophic lateral scelrosis IL162408A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33938301P 2001-12-11 2001-12-11
US34737102P 2002-01-11 2002-01-11
PCT/US2002/039970 WO2003049705A2 (en) 2001-12-11 2002-12-02 Use of pramipexole to treat amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
IL162408A0 true IL162408A0 (en) 2005-11-20

Family

ID=26991607

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16240802A IL162408A0 (en) 2001-12-11 2002-12-02 Use of pramipexole to treat amyotrophic lateral scelrosis

Country Status (20)

Country Link
US (4) US7157480B2 (hu)
EP (4) EP2305253A1 (hu)
JP (2) JP4500543B2 (hu)
KR (1) KR20040066890A (hu)
CN (1) CN1617720A (hu)
AT (1) ATE480235T1 (hu)
AU (1) AU2002360600B2 (hu)
CA (1) CA2468747C (hu)
CY (1) CY1111237T1 (hu)
DE (1) DE60237635D1 (hu)
DK (1) DK1453505T3 (hu)
ES (2) ES2351303T3 (hu)
HK (1) HK1150153A1 (hu)
HU (1) HUP0500001A3 (hu)
IL (1) IL162408A0 (hu)
MX (1) MXPA04005572A (hu)
PL (1) PL374310A1 (hu)
PT (1) PT1453505E (hu)
RU (1) RU2004121177A (hu)
WO (1) WO2003049705A2 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374310A1 (en) * 2001-12-11 2005-10-03 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ES2334061T3 (es) * 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
EP1940398A1 (de) * 2005-10-18 2008-07-09 Boehringer Ingelheim International GmbH Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) * 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
EP2465500A1 (en) * 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2016210640B2 (en) * 2006-12-14 2018-02-22 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
AU2007333050B2 (en) * 2006-12-14 2013-08-29 Knopp Biosciences Llc Compositions and methods of using (R)-pramipexole
AU2013209376B2 (en) * 2006-12-14 2016-05-05 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
JP2010521493A (ja) * 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． （６ｒ）−４，５，６，７−テトラヒドロ−ｎ６−プロピル−２，６−ベンゾチアゾール−ジアミンの放出調節製剤およびそれらの使用方法
GB0811642D0 (en) * 2008-06-25 2008-07-30 Univ Edinburgh Assay
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
JP2012530723A (ja) * 2009-06-19 2012-12-06 ノップ ニューロサイエンシーズ、インク． 筋萎縮性側索硬化症を治療するための組成物及び方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2887954B1 (en) 2012-08-23 2020-05-06 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions
US10874669B2 (en) 2012-11-29 2020-12-29 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
CA2885653A1 (en) 2012-11-29 2014-06-05 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
PT3019167T (pt) 2013-07-12 2021-03-04 Knopp Biosciences Llc Tratamento de níveis elevados de eosinófilos e/ou basófilos
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CN111278425B (zh) 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560420A (en) 1896-05-19 Steam and oil separator
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
EP0186087B1 (de) 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
EE04177B1 (et) * 1995-10-26 2003-12-15 Sanofi 1-(2-naft-2-üületüül)-4-(3-trifluorometüülfenüül)-1,2,3,6-tetrahüdropüridiini kasutamine ravimite valmistamiseks amüotroofilise lateraalskleroosi raviks
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
ID29852A (id) * 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
CA2415815A1 (en) * 2000-07-06 2002-01-17 Nigel H. Greig Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
PL374310A1 (en) * 2001-12-11 2005-10-03 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
EP1610791B1 (en) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ES2334061T3 (es) * 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).

Also Published As

Publication number Publication date
EP2246053A1 (en) 2010-11-03
EP2246053B1 (en) 2013-09-18
US20110301210A1 (en) 2011-12-08
CY1111237T1 (el) 2015-06-11
CN1617720A (zh) 2005-05-18
WO2003049705A2 (en) 2003-06-19
AU2002360600A1 (en) 2003-06-23
HUP0500001A3 (en) 2005-11-28
WO2003049705A3 (en) 2004-01-29
US20130172394A1 (en) 2013-07-04
EP1453505A4 (en) 2007-01-10
HUP0500001A2 (hu) 2005-04-28
PL374310A1 (en) 2005-10-03
DK1453505T3 (da) 2010-11-15
US7157480B2 (en) 2007-01-02
CA2468747C (en) 2011-05-31
PT1453505E (pt) 2010-12-16
US20050032856A1 (en) 2005-02-10
KR20040066890A (ko) 2004-07-27
JP2005516911A (ja) 2005-06-09
ES2351303T3 (es) 2011-02-02
EP1453505A2 (en) 2004-09-08
JP4500543B2 (ja) 2010-07-14
CA2468747A1 (en) 2003-06-19
AU2002360600B2 (en) 2007-11-29
RU2004121177A (ru) 2005-03-10
EP2305253A1 (en) 2011-04-06
JP2010031059A (ja) 2010-02-12
EP2305252A1 (en) 2011-04-06
US20070105918A1 (en) 2007-05-10
EP1453505B1 (en) 2010-09-08
HK1150153A1 (en) 2011-11-04
ATE480235T1 (de) 2010-09-15
ES2432527T3 (es) 2013-12-04
MXPA04005572A (es) 2004-12-06
DE60237635D1 (de) 2010-10-21

Similar Documents

Publication Publication Date Title
HK1150153A1 (en) Use of pramipexole to treat amyotrophic lateral sclerosis
GB0108592D0 (en) Therapeutic agents
BG108493A (en) Beta-amino tetrahydroimidazolo(1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2001252958A1 (en) Compounds and methods to treat alzheimer's disease
IL132797A0 (en) Compounds and methods for the inhibition of the expression of vcam-1
WO2002002512A3 (en) Compounds to treat alzheimer's disease
MXPA03008135A (es) Combinacion de analogos de epotilona y agentes quimioterapeuticos para tratamiento de enfermedades proliferativas.
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
PT1465626E (pt) Composições farmacêuticas (kit) que compreendem compostos di-hidropiridinona e um agente imunorregulador (ou antiinflamatório) e suas utilizações
AU2001271686A1 (en) Compounds to treat alzheimer's disease
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
NZ335981A (en) Ketobenzamides as calpain inhibitors
WO2002002520A8 (en) Compounds to treat alzheimer's disease
EP1068304A4 (en) TREATMENT OF PARASITAL DISEASES BY INHIBITING CYSTEIN PROTEASES OF THE PAPAIN OVERFAMILY
DE69805672D1 (de) Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
MY139368A (en) Novel cyclohexyl sulphones
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
WO2003055440A3 (en) Compositions and methods for the treatement of immune related diseases
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
ES2190373A1 (es) Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline